Ricevi le ultime notizie sulle azioni Shuttle Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SHPH

Ultime notizie per

Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals Holdings Inc

SIHUAN PHARM HOLDINGS GP by Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd

SIHUAN PHARM HLDGS ADR by Sihuan Pharmaceutical Holdings Group Ltd.

News

Legal

Press Releases

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Health Care

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

General

Shuttle Pharma Provides Corporate Update

Management

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Markets

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Financing

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

SHPH

Aditxt

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

ETHZilla

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Medicus Pharma

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Comments

Shuttle Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO